Gene Therapy, Venture

Jude Samulski’s gene therapy company just raised $235M for clinical development

A gene therapy company that’s played a key role in backing treatments now owned by Novartis and Pfizer is stepping up this morning with a monster venture raise aimed at making it a leading clinical developer in one of the hottest fields in biotech.

Asklepios Biopharmaceutical, which prefers to be less formally known as AskBio, sold a minority stake in the company to TPG and Vida Ventures for $225 million. And the company’s founders and board members are putting in another $10 million — skin in the game.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->